Changfeng Pharmaceutical (02652) has completed the placement of 21.477 million new H shares, raising approximately HK$295 million.
Changfeng Pharmaceutical (02652) announced that it has completed the placement of 21.7477 million new H shares on August 6, 2026, at a placement price of HKD 13.82 per H share, raising approximately HKD 295 million.
Changfeng Pharmaceutical (02652) announced that it has completed the placement of 21.7477 million new H-shares on August 6, 2026, at a placement price of HK$13.82 per H-share, raising approximately HK$295 million net.
Related Articles
Takeda (TAK.US) has received approval from the U.S. FDA for Oxybate for the treatment of type 1 narcolepsy.
Yibin Tianyuan Group (002386.SZ) has received approval from the Shenzhen Stock Exchange for its application to issue stocks to specific objects in 2026.
CGII HLDGS (01940) issued a positive profit warning, expecting after-tax net profit for the first half of the year to be no less than 100 million yuan.
Takeda (TAK.US) has received approval from the U.S. FDA for Oxybate for the treatment of type 1 narcolepsy.
Yibin Tianyuan Group (002386.SZ) has received approval from the Shenzhen Stock Exchange for its application to issue stocks to specific objects in 2026.
CGII HLDGS (01940) issued a positive profit warning, expecting after-tax net profit for the first half of the year to be no less than 100 million yuan.
RECOMMEND
